KRAS and lung carcinoma: A more recent study of a large patient cohort (n = 330) with advanced KRAS-mutant lung cancer identified co-mutated KEAP1 as an independent prognostic marker for poorer survival [HR = 1.96; P < 0.001] and as being associated with less response to chemotherapy [HR = 1.64; P = 0.03] and immune therapy [HR = 3.54; P = 0.003] (30).